TARO NYSE

Taro Pharmaceutical Industries Ltd. operates as a scientifically-driven pharmaceutical enterprise, specializing in the development, manufacturing, and commercialization of both prescription and over-the-counter medications. Its market reach spans the United States, Canada, Israel, and various other international territories. The company also produces active pharmaceutical ingredients (APIs), primarily for integration into its own finished dosage form products. Its extensive product catalog addresses a broad spectrum of medical conditions and therapeutic areas, encompassing treatments for allergies, pain (analgesic), bacterial and fungal infections (antibacterial, antibiotic, antifungal), seizures (anticonvulsant), nausea (antiemetic), inflammation (anti-inflammatory), cancer (anti-cancer, topical anti-neoplastic), blood clot prevention (antiplatelet agent), fever reduction (antipyretic), cardiovascular issues, central nervous system disorders, hormonal regulation (corticosteroid, endocrine), cosmetic applications, coughs and colds, dermatological complaints, fluid management (diuretic), gastrointestinal problems, constipation (laxative), severe pain (narcotics), neuropathic pain, neuropsychiatric conditions, and sleep/anxiety management (sedative/hypnotic). These pharmaceutical goods are available in numerous formats, including capsules, creams, drops, emulsions, gels (and gel kits), granules, injectables, lotions, oils, ointments, pastes, powders (and powders for solution), rectal suppositories, shampoos, solutions (and solutions for infusion), sprays, suspensions, syrups, tablets, toothpastes and mouthwashes, topical foams, and topical solutions. Taro distributes and sells its products directly to a wide array of clients, such as pharmaceutical wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, other direct purchasers, and various healthcare institutions and private pharmacies. The company was established in 1950, with its main offices situated in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a wholly-owned subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.